ISPE Pharma 4.0 大会前瞻:Octapharma 与 INOSIM 的整体数字孪生实践
Octapharma 与 INOSIM 将在 2026 ISPE Pharma 4.0 与生物制药大会(12 月 10 至 11 日,柏林及线上)分享整体数字孪生实践,把生产仿真从设计阶段延伸到日常运营。
Pharma 4.0™ in Action: How Holistic Digital Twins Are Transforming Biopharma Manufacturing
来源
ISPE iSpeak Blog(Pharmaceutical Engineering)| 发布日期 2026-10-27
URL
ispe.org/pharmaceutical-engineering/ispeak/pharma-40tm-action-how-holistic-digital-twins-are-transforming
讲者与场合
Peer Sander(INOSIM GmbH)、Dennis Meister(Octapharma)| 2026 ISPE Pharma 4.0™ and Biopharma Conference(2026 年 12 月 10 至 11 日,德国柏林及线上)会前预稿
图:2026 ISPE Pharma 4.0 与生物制药大会讲者宣传照,主讲人 Peer Sander,INOSIM GmbH 技术事务负责人(图源:ispe.org)
As pharmaceutical and biopharmaceutical manufacturers face increasing global competition, rising operational costs, and growing regulatory complexity, the need for smarter, more integrated manufacturing strategies has never been greater. Organizations are under pressure to improve efficiency and throughput while maintaining the robust quality systems and operational reliability required in highly regulated environments.
随着全球竞争加剧、运营成本上升与监管复杂度提高,制药与生物制药企业比以往任何时候都更需要更智能、更整合的生产策略。企业既要提升效率与产量,又要守住高度受监管环境下必需的稳健质量体系与运营可靠性。
These challenges will be at the center of discussion during the 2026 ISPE Pharma 4.0™ and Biopharma Conference, taking place 10-11 December in Berlin, Germany, and virtually. Bringing together industry leaders, technology experts, and manufacturing professionals, the conference will showcase practical applications of digital transformation across the pharmaceutical lifecycle.
这些挑战将是 2026 ISPE Pharma 4.0™ 与生物制药大会的核心议题。大会于 12 月 10 日至 11 日在德国柏林举行,并设线上参会。大会将汇聚行业领袖、技术专家与生产专业人员,展示数字化转型在整个制药生命周期中的实际应用。
Among the featured sessions is “Pharma 4.0™ in Engineering and Operations: Holistic Digital Twins,” presented by Peer Sander, INOSIM GmbH, and Dennis Meister, Octapharma. The session, which is part of the Pharma 4.0™ in Action: Biopharma Manufacturing Transformation track, will explore how digital twin technology is helping manufacturers optimize facility design, improve operational performance, and generate measurable business value across the entire plant lifecycle.
重点场次之一是「Pharma 4.0™ in Engineering and Operations: Holistic Digital Twins」,由 INOSIM GmbH 的 Peer Sander 与 Octapharma 的 Dennis Meister 联合主讲。该场次属于「Pharma 4.0™ in Action: Biopharma Manufacturing Transformation」分论坛,将探讨数字孪生技术如何帮助生产企业优化设施设计、改善运营绩效,并在工厂全生命周期内创造可衡量的业务价值。
一、应对现代生产挑战
Addressing Modern Manufacturing Challenges
Today’s pharmaceutical facilities are more complex than ever before. Manufacturers must balance increasing demand for medicines with strict regulatory expectations, evolving production technologies, and the need to remain cost competitive in a global marketplace.
今天的制药设施比以往任何时候都复杂。生产企业必须在日益增长的药品需求、严格的监管预期、不断演进的生产技术,以及保持全球市场成本竞争力之间取得平衡。
According to Peer Sander, pharmaceutical manufacturers are experiencing growing pressure to achieve more efficient and optimized production while continuing to meet stringent quality and compliance requirements. At the same time, the high value of pharmaceutical products makes operational reliability and process robustness critical business priorities.
据 Peer Sander 介绍,制药企业正承受越来越大的压力:既要实现更高效、更优化的生产,又要持续满足严格的质量与合规要求。与此同时,药品的高价值使运营可靠性与工艺稳健性成为关键的业务优先项。
Successfully balancing these objectives can be particularly challenging in modern facilities, where interconnected processes, sophisticated equipment, and complex workflows create new operational demands. As a result, many organizations are looking beyond isolated digital tools and pursuing fully integrated Pharma 4.0™ strategies that connect engineering, manufacturing, and operational decision-making.
在现代设施里平衡这些目标尤其困难:相互关联的工序、复杂的设备与复杂的工作流带来新的运营要求。因此,许多组织不再满足于孤立的单点数字工具,转向追求把工程、生产与运营决策连接起来的完全整合的 Pharma 4.0™ 策略。
The session will demonstrate how digital twins are helping bridge this gap.
该场次将展示数字孪生如何帮助弥合这一差距。
二、走出仿真,进入日常运营
Moving Beyond Simulation
Simulation has long been used to support facility design and process optimization. Traditionally, however, these models have been utilized primarily during project planning phases and then set aside once facilities become operational.
仿真长期被用于支持设施设计与工艺优化。但传统上,这些模型主要在项目规划阶段使用,设施投入运行后即被搁置。
The approach presented by Octapharma and INOSIM extends simulation far beyond the design stage.
Octapharma 与 INOSIM 展示的方法,把仿真的应用范围远远扩展到设计阶段之外。
As Sander explains, the organizations have developed a methodology that combines production performance, efficiency, and operational robustness through advanced production simulation. What makes the approach particularly noteworthy is that simulation is not limited to offline engineering activities. Instead, simulation models are brought into day-to-day operations, creating a true digital twin application that continuously supports manufacturing execution and decision-making.
据 Sander 解释,双方已形成一套方法,用先进的生产仿真把生产绩效、效率与运营稳健性结合在一起。该方法的特别之处在于:仿真不再局限于线下工程活动,而是进入日常运营,形成一个持续支持生产执行与决策的真正的数字孪生应用。
This evolution represents an important step in the practical implementation of Pharma 4.0™ principles. By creating a dynamic digital representation of manufacturing operations, organizations can gain greater visibility into plant performance, evaluate potential outcomes before making decisions, and proactively identify opportunities for improvement.
这一演进是 Pharma 4.0™ 原则走向实际实施的重要一步。通过为生产运营建立动态的数字表达,组织可以更清楚地看到工厂绩效,在决策前评估可能的结果,并主动识别改进机会。
Rather than relying solely on retrospective analysis, manufacturers can use digital twins to support real-time operational awareness and more informed decision-making.
生产企业可以不再只依赖事后分析,而是用数字孪生支持实时的运营感知与更有依据的决策。
三、在工厂全生命周期创造价值
Creating Value Across the Plant Lifecycle
One of the key themes of the session is the value that digital twins can deliver throughout the entire facility lifecycle.
该场次的关键主题之一,是数字孪生在整个设施生命周期中能带来的价值。
The journey often begins during engineering and capital project phases, where sophisticated simulation models can be used to evaluate facility designs, production strategies, and capacity requirements before construction or implementation decisions are finalized.
这条路通常从工程与资本项目阶段开始:在建设或实施决策敲定之前,用精细的仿真模型评估设施设计、生产策略与产能需求。
This approach enables companies to identify potential constraints earlier, evaluate alternative scenarios, and develop more efficient facility concepts. The result can be manufacturing systems that achieve higher performance while helping minimize capital expenditures.
这一做法让企业更早发现潜在约束、评估备选方案、形成更高效的设施概念,其结果可能是生产系统在取得更高绩效的同时,把资本支出降到更低。
However, the benefits do not end once a facility begins operating.
但收益并不随设施投产而结束。
The session will highlight how Octapharma has expanded the use of simulation into live production environments, allowing teams to continuously optimize manufacturing performance. This operational digital twin approach supports improved planning, more efficient resource utilization, and enhanced visibility into production activities.
该场次将重点介绍 Octapharma 如何把仿真的使用扩展到实时生产环境,让团队能够持续优化生产绩效。这种运营型数字孪生方法支持更好的计划、更高效的资源利用,以及对生产活动的更高可见性。
By connecting simulation models with real-world operational data, manufacturers can establish a powerful framework for continuous improvement.
把仿真模型与真实运营数据连接起来,生产企业就能建立一个有力的持续改进框架。
四、支持更聪明的运营决策
Supporting Smarter Operational Decisions
As facilities become increasingly data-rich, one of the greatest opportunities lies in turning information into actionable insights.
设施产生的数据越来越丰富,最大的机会之一在于把信息转化为可执行的洞见。
According to Sander, operational digital twins can help organizations continuously improve production planning while enabling the real-time identification and avoidance of delays, bottlenecks, and GMP-relevant deviations. These capabilities allow manufacturing teams to address issues proactively rather than reactively, reducing disruptions and supporting more predictable operations.
据 Sander 介绍,运营型数字孪生可以帮助组织持续改进生产计划,并实时识别和规避延误、瓶颈与 GMP 相关偏差。这些能力让生产团队主动而非被动地处理问题,减少中断,让运营更可预期。
The ability to evaluate alternative scenarios before implementing changes also provides a valuable advantage. Manufacturers can assess the potential impact of scheduling decisions, equipment availability, resource constraints, and process changes in a virtual environment before making adjustments on the plant floor.
在实施变更前评估备选场景也提供了重要优势。生产企业可以在虚拟环境中先评估排产决策、设备可用性、资源约束与工艺变更的潜在影响,再到车间做调整。
This enhanced visibility supports more effective decision-making while helping maintain the quality and compliance standards expected in pharmaceutical manufacturing.
这种增强的可见性支持更有效的决策,同时帮助维持制药生产应有的质量与合规标准。
Attendees will gain insight into how these capabilities translate into tangible operational improvements, including:
参会者将了解这些能力如何转化为实际的运营改进,包括:
- Improved production planning and scheduling
- Enhanced resource and asset utilization
- Earlier identification of bottlenecks and operational constraints
- Reduced risk of delays and GMP-relevant deviations
- Greater operational transparency
- Data-driven decision-making across manufacturing activities
- Increased throughput while maintaining robust and reliable operations
· 更好的生产计划与排程
· 更高的资源与资产利用率
· 更早识别瓶颈与运营约束
· 降低延误与 GMP 相关偏差的风险
· 更高的运营透明度
· 贯穿生产活动的数据驱动决策
· 在保持稳健可靠运营的同时提高产量
五、Pharma 4.0 落到实处的例子
A Practical Example of Pharma 4.0™ in Action
While discussions surrounding Industry 4.0 and Pharma 4.0™ often focus on future possibilities, this session emphasizes real-world implementation.
围绕工业 4.0 与 Pharma 4.0™ 的讨论常常聚焦未来的可能性,该场次强调的是现实世界的实施。
Through practical examples and case studies, Sander and Meister will demonstrate how digital transformation initiatives can move beyond strategy and deliver measurable business outcomes. Attendees will learn how a holistic approach to digital twins can create value from early engineering design through ongoing production operations.
通过实例与案例研究,Sander 与 Meister 将展示数字化转型举措如何超越战略层面、交付可衡量的业务成果。参会者将了解数字孪生的整体方法如何从早期工程设计开始,一直创造价值到持续的生产运营。
The presentation also highlights an important shift occurring across the industry. Rather than viewing digital technologies as standalone projects, leading organizations are increasingly integrating them into broader operational frameworks that support long-term business objectives.
报告还指出了行业正在发生的一个重要转变:领先组织不再把数字技术当作独立项目,而是越来越把它们整合进支撑长期业务目标的更大的运营框架。
For companies seeking to strengthen competitiveness, improve operational excellence, and build more resilient manufacturing systems, these lessons offer valuable insights into what successful Pharma 4.0™ implementation looks like in practice.
对希望增强竞争力、改善卓越运营、建成更有韧性的生产体系的企业来说,这些经验说明了成功的 Pharma 4.0™ 实施在实践中是什么样子。
六、柏林见
Join the Conversation in Berlin
图:2026 ISPE Pharma 4.0 与生物制药大会主视觉,12 月 10 至 11 日,德国柏林(图源:ispe.org)
The 2026 ISPE Pharma 4.0™ and Biopharma Conference will provide a unique opportunity to explore how digital technologies, advanced manufacturing strategies, and data-driven decision-making are shaping the future of pharmaceutical operations.
2026 ISPE Pharma 4.0™ 与生物制药大会提供了一个独特的机会,去探究数字技术、先进生产策略与数据驱动决策正在如何塑造制药运营的未来。
The session reflects one of the central themes of the 2026 ISPE Pharma 4.0™ and Biopharma Conference: moving beyond digital transformation concepts to real-world implementation. By sharing practical experiences and measurable outcomes, Sander and Meister will demonstrate how digital twin technologies are helping biopharmaceutical manufacturers improve efficiency, robustness, and competitiveness in an increasingly complex operating environment.
该场次体现了大会的核心主题之一:从数字化转型概念走向现实实施。Sander 与 Meister 将分享实践经验与可衡量的成果,展示数字孪生技术如何帮助生物制药企业在日益复杂的运营环境中提升效率、稳健性与竞争力。
For professionals involved in engineering, manufacturing, digital transformation, operations, quality, and technology implementation, this session will provide valuable insights into how digital twins are driving measurable improvements in efficiency, performance, and operational robustness.
对从事工程、生产、数字化转型、运营、质量与技术实施的专业人士,该场次将提供有价值的参考:数字孪生如何在效率、绩效与运营稳健性上带来可衡量的改进。
— 完 —
说明:全文照译,无删节;「Pharma 4.0™」为 ISPE 注册标识,章节标题保留英文原题;报名与议程见 ISPE 大会官网(ispe.org/conferences/2026-pharma-40-biopharma-conference)。配图两张均取自原文页面,图源 ispe.org。
来源:小南AI实验室 · mp.weixin.qq.com